TRANSDERMAL ABSORPTION OF THE PROGESTIN ST-1435 - THERAPEUTIC SERUM STEROID CONCENTRATIONS AND HIGH EXCRETION OF THE STEROID IN SALIVA

被引:16
作者
HAUKKAMAA, M
LAURIKKAROUTTI, M
HEIKINHEIMO, O
机构
[1] Steroid Research Laboratory Department
关键词
D O I
10.1016/0010-7824(91)90017-A
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
The synthetic progestin ST-1435 was administered transdermally to six healthy women during the late luteal phase. The steroid was applied to the periumbilical area in a commercial gel ("Progestogel"), also containing progesterone. Single doses of 2.3, 4.5 and 9.0 mg of ST-1435 were given in three experiments and repeated doses of 2.3 mg of ST-1435 for five days were given in another three experiments. Samples of serum and saliva were collected and the concentrations of ST-1435 and progesterone were determined by radioimmunoassays. Transdermal absorption of the synthetic progestin ST-1435 was shown to result in serum steroid concentrations high enough for therapeutic purposes. The concentration of ST-1435 in serum was still high 24 hours after application, reflecting sustained release of the steroid from the skin. In the five-day experiments, relatively constant serum levels were achieved in different individuals, and a single dose per day seems sufficient. High excretion of ST-1435 in saliva was found two hours after gel application. However, the concentrations of serum and salivary ST-1435 were not directly correlated in different individuals. Transdermal application of ST-1435 might offer a good alternative for systemic progestin treatment.
引用
收藏
页码:269 / 276
页数:8
相关论文
共 18 条
[1]   TRANSDERMAL TESTOSTERONE THERAPY IN THE TREATMENT OF MALE HYPOGONADISM [J].
AHMED, SR ;
BOUCHER, AE ;
MANNI, A ;
SANTEN, RJ ;
BARTHOLOMEW, M ;
DEMERS, LM .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1988, 66 (03) :546-551
[2]  
COUTINHO EM, 1976, INT J FERTIL, V21, P103
[3]   LONG-TERM EFFECTS OF PERCUTANEOUS ESTROGENS AND ORAL PROGESTERONE ON SERUM-LIPOPROTEINS IN POSTMENOPAUSAL WOMEN [J].
JENSEN, J ;
RIIS, BJ ;
STROM, V ;
NILAS, L ;
CHRISTIANSEN, C .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1987, 156 (01) :66-71
[4]  
LAHTEENMAKI P, 1981, CONTRACEPTION, V23, P63
[5]   PITUITARY AND OVARIAN-FUNCTION DURING CONTRACEPTION WITH ONE SUBCUTANEOUS IMPLANT RELEASING A-PROGESTIN, ST-1435 [J].
LAHTEENMAKI, P ;
WEINER, E ;
LAHTEENMAKI, P ;
JOHANSSON, EDB ;
LUUKKAINEN, T .
CONTRACEPTION, 1982, 25 (03) :299-306
[6]   PHARMACOKINETIC OBSERVATIONS ON ST-1435 ADMINISTERED SUBCUTANEOUSLY AND INTRAVAGINALLY [J].
LAHTEENMAKI, PLA ;
KURUNMAKI, H ;
LAHTEENMAKI, P ;
TOIVONEN, J ;
LUUKKAINEN, T .
CONTRACEPTION, 1984, 30 (04) :381-389
[7]   SERUM NON-PROTEIN BOUND PERCENTAGE AND DISTRIBUTION OF THE PROGESTIN-ST-1435 - NO EFFECT OF ST-1435 TREATMENT ON PLASMA SHBG AND CBG BINDING-CAPACITIES [J].
LAHTEENMAKI, PLA ;
HAMMOND, GL ;
LUUKKAINEN, T .
ACTA ENDOCRINOLOGICA, 1983, 102 (02) :307-313
[8]   INTESTINAL-ABSORPTION OF ST-1435 IN RATS [J].
LAHTEENMAKI, PLA .
CONTRACEPTION, 1984, 30 (02) :143-151
[9]  
LAHTEENMAKI PLA, 1986, THESIS U HELSINKI HE, P35
[10]   IN-VIVO STUDIES ON PROGESTERONE METABOLISM BY HUMAN SKIN [J].
MAUVAISJARVIS, P ;
BAUDOT, N ;
BERCOVICI, JP .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1969, 29 (12) :1580-+